Actuate Therapeutics financials
$0.6860−6.82%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q1 '11 Sep 30 | Q4 '10 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $13.1M | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $10.6M | — |
| Gross margin | — | — | — | — | — | — | — | — | 81.1% | — |
| Operating income | -$4.9M | -$5.7M | -$4.7M | -$5.5M | -$6.0M | -$6.4M | -$6.6M | -$5.4M | $4.9M | — |
| Net income | -$4.9M | -$5.6M | -$4.6M | -$5.4M | -$5.9M | -$6.3M | -$6.4M | -$6.0M | $4.8M | — |
| Net margin | — | — | — | — | — | — | — | — | 37.0% | — |
| Diluted EPS | $-0.20 | $-0.24 | $-0.19 | $-0.25 | $-0.30 | $-0.32 | $-0.33 | $-0.55 | $0.22 | — |
| EBITDA | -$4.9M | -$5.7M | -$4.7M | -$5.5M | -$6.0M | -$6.4M | -$6.6M | -$5.4M | $5.0M | $0.00 |
| Operating cash flow | -$4.4M | -$5.0M | -$3.7M | -$6.7M | -$4.2M | -$4.6M | -$4.8M | -$9.1M | -$600.0K | — |
| Free cash flow | -$4.4M | -$5.0M | -$3.7M | -$6.7M | -$4.2M | -$4.6M | -$4.8M | -$9.1M | -$829.0K | — |
| Diluted shares | 23.9M | 23.5M | 23.5M | 21.4M | 19.6M | 19.5M | 19.6M | 10.8M | 22.4M | 22.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.4M | $8.1M | $13.2M | $16.9M | $6.5M | $3.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $37.1K | $32.1K | $27.0K | $22.0K | $71.0K | $487.8K |
| Total assets | $5.2M | $8.9M | $14.0M | $17.7M | $7.0M | $4.5M |
| Total liabilities | $4.2M | $5.1M | $6.1M | $6.8M | $9.6M | $9.6M |
| Shareholders' equity | $989.2K | $3.8M | $7.9M | $10.9M | -$2.7M | -$5.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology